Literature DB >> 9527275

The influence of recombinant human erythropoietin on tumor necrosis factor alpha and interleukin-10 production by whole blood cell cultures in hemodialysis patients.

E Bryl1, J Myśliwska, A Debska-Slizień, D Rachoń, B Bułło, S Lizakowski, A Myśliwski, B Rutkowski.   

Abstract

Impaired immunological response in hemodialysis (HD) patients, which leads to inappropriate cytokine production, is partially caused by the hyperstimulation of both T lymphocytes and monocytes/macrophages. Recent data suggest that human recombinant erythropoietin (rhEPO) may have an immunological action. The goal of our study was to estimate the influence of rhEPO treatment on the production of the inflammatory cytokine tumor necrosis factor alpha (TNFalpha) and antiinflammatory cytokin interleukin-10 (IL-10) in 10 HD patients receiving rhEPO for 6 months. The levels of cytokines were measured in the in vitro cultures of whole blood. The level of IL-10 increased in all treated patients during the therapy, and it was accompanied by a transitory decrease of TNFalpha. The results of our studies suggest that rhEPO may reduce the inflammatory process by decreasing production of TNFalpha and increasing production of IL-10.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9527275     DOI: 10.1046/j.1525-1594.1998.06002.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  9 in total

1.  Erythropoietin receptor is detectable on peripheral blood lymphocytes and its expression increases in activated T lymphocytes.

Authors:  Katarzyna A Lisowska; Ewa Bryl; Jacek M Witkowski
Journal:  Haematologica       Date:  2011-03       Impact factor: 9.941

2.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress.

Authors:  A L Sirén; M Fratelli; M Brines; C Goemans; S Casagrande; P Lewczuk; S Keenan; C Gleiter; C Pasquali; A Capobianco; T Mennini; R Heumann; A Cerami; H Ehrenreich; P Ghezzi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

Review 3.  Neuroprotective effects of erythropoiesis-stimulating agents in term and preterm neonates.

Authors:  Amber M Messier; Robin K Ohls
Journal:  Curr Opin Pediatr       Date:  2014-04       Impact factor: 2.856

4.  Hemodialysis affects phenotype and proliferation of CD4-positive T lymphocytes.

Authors:  Katarzyna A Lisowska; Alicja Dębska-Ślizień; Aleksandra Jasiulewicz; Zbigniew Heleniak; Ewa Bryl; Jacek M Witkowski
Journal:  J Clin Immunol       Date:  2011-10-13       Impact factor: 8.317

5.  Effects of intraosseous erythropoietin during hemorrhagic shock in swine.

Authors:  Vesna Borovnik-Lesjak; Kasen Whitehouse; Alvin Baetiong; Yang Miao; Brian M Currie; Sathya Velmurugan; Jeejabai Radhakrishnan; Raúl J Gazmuri
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

6.  The influence of a single hemodialysis procedure on human T lymphocytes.

Authors:  Katarzyna A Lisowska; Małgorzata Pindel; Krzysztof Pietruczuk; Izabella Kuźmiuk-Glembin; Hanna Storoniak; Alicja Dębska-Ślizień; Jacek M Witkowski
Journal:  Sci Rep       Date:  2019-03-25       Impact factor: 4.379

7.  Changes in the Expression of Transcription Factors Involved in Modulating the Expression of EPO-R in Activated Human CD4-Positive Lymphocytes.

Authors:  Katarzyna A Lisowska; Joanna E Frackowiak; Anna Mikosik; Jacek M Witkowski
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

8.  The influence of recombinant human erythropoietin on apoptosis and cytokine production of CD4+ lymphocytes from hemodialyzed patients.

Authors:  Katarzyna A Lisowska; Alicja Dębska-Ślizień; Aleksandra Jasiulewicz; Agnieszka Daca; Ewa Bryl; Jacek M Witkowski
Journal:  J Clin Immunol       Date:  2012-11-20       Impact factor: 8.317

Review 9.  A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19.

Authors:  Adeleh Sahebnasagh; Mojataba Mojtahedzadeh; Farhad Najmeddin; Atabak Najafi; Mohammadreza Safdari; Hassan Rezai Ghaleno; Solomon Habtemariam; Ioana Berindan-Neagoe; Seyed Mohammad Nabavi
Journal:  Arch Med Res       Date:  2020-08-11       Impact factor: 2.235

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.